Clinical trials
Phase 1 Prostatic Neoplasms, Castration-Resistant trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 7 |
| Completed | 6 |
| Terminated | 5 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 3 |
| MacroGenics | 2 |
| Nuvation Bio Inc. | 2 |
| Aragon Pharmaceuticals, Inc. | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Boehringer Ingelheim | 1 |
| Bristol-Myers Squibb | 1 |
| Celgene | 1 |
| Endocyte | 1 |
| Erasmus Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms, Castration-Resistant | 23 |
| Prostatic Neoplasms | 11 |
| Neoplasms | 6 |
| Breast Neoplasms | 3 |
| Genital Neoplasms, Male | 3 |
| Neoplasms by Site | 3 |
| Prostatic Diseases | 3 |
| Urogenital Neoplasms | 3 |
| Carcinoma, Renal Cell | 2 |
| Genital Diseases, Male | 2 |
Trials
Showing 51 to 23 of 23. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.